Eli Lilly and Company
LLY
$1,059.70
$16.411.57%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.60B | 15.56B | 12.73B | 13.53B | 11.44B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.60B | 15.56B | 12.73B | 13.53B | 11.44B |
| Cost of Revenue | 3.01B | 2.45B | 2.22B | 2.40B | 2.17B |
| Gross Profit | 14.59B | 13.11B | 10.50B | 11.13B | 9.27B |
| SG&A Expenses | 2.63B | 2.65B | 2.36B | 2.31B | 1.98B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.10B | 8.43B | 7.32B | 7.74B | 6.89B |
| Operating Income | 8.50B | 7.13B | 5.41B | 5.80B | 4.55B |
| Income Before Tax | 7.23B | 6.78B | 3.46B | 5.04B | 1.59B |
| Income Tax Expenses | 1.65B | 1.12B | 696.80M | 628.90M | 618.10M |
| Earnings from Continuing Operations | 5.58B | 5.66B | 2.76B | 4.41B | 970.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.58B | 5.66B | 2.76B | 4.41B | 970.30M |
| EBIT | 8.50B | 7.13B | 5.41B | 5.80B | 4.55B |
| EBITDA | 8.97B | 7.60B | 5.87B | 6.28B | 5.02B |
| EPS Basic | 6.22 | 6.30 | 3.07 | 4.88 | 1.08 |
| Normalized Basic EPS | 5.72 | 4.74 | 3.62 | 3.87 | 3.04 |
| EPS Diluted | 6.21 | 6.29 | 3.06 | 4.88 | 1.07 |
| Normalized Diluted EPS | 5.71 | 4.73 | 3.62 | 3.87 | 3.03 |
| Average Basic Shares Outstanding | 896.90M | 897.90M | 898.70M | 903.16M | 901.00M |
| Average Diluted Shares Outstanding | 898.80M | 899.80M | 900.60M | 903.16M | 905.00M |
| Dividend Per Share | 1.50 | 1.50 | 1.50 | 1.30 | 1.30 |
| Payout Ratio | 24.10% | 23.80% | 48.79% | 26.49% | 120.63% |